• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神分裂症患者受体的基因多态性与抗精神病药物所致代谢功能障碍

Genetic Polymorphisms of Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia.

作者信息

Paderina Diana Z, Boiko Anastasiia S, Pozhidaev Ivan V, Bocharova Anna V, Mednova Irina A, Fedorenko Olga Yu, Kornetova Elena G, Loonen Anton J M, Semke Arkadiy V, Bokhan Nikolay A, Ivanova Svetlana A

机构信息

Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634014 Tomsk, Russia.

Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634050 Tomsk, Russia.

出版信息

J Pers Med. 2021 Mar 5;11(3):181. doi: 10.3390/jpm11030181.

DOI:10.3390/jpm11030181
PMID:33807811
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7999828/
Abstract

BACKGROUND

Antipsychotic-induced metabolic syndrome (MetS) is a multifactorial disease with a genetic predisposition. Serotonin and its receptors are involved in antipsychotic-drug-induced metabolic disorders. The present study investigated the association of nine polymorphisms in the four 5-hydroxytryptamine receptor () genes , , , and and the gene encoding for the serotonin transporter with MetS in patients with schizophrenia.

METHODS

A set of nine single-nucleotide polymorphisms of genes of the serotonergic system was investigated in a population of 475 patients from several Siberian regions (Russia) with a clinical diagnosis of schizophrenia. Genotyping was performed and the results were analyzed using chi-square tests.

RESULTS

Polymorphic variant rs521018 () was associated with higher body mass index in patients receiving long-term antipsychotic therapy, but not with drug-induced metabolic syndrome. Rs1150226 () was also associated but did not meet Hardy-Weinberg equilibrium.

CONCLUSIONS

Our results indicate that allelic variants of genes may have consequences on metabolic parameters. MetS may have too complex a mechanistic background to be studied without dissecting the syndrome into its individual (causal) components.

摘要

背景

抗精神病药物所致代谢综合征(MetS)是一种具有遗传易感性的多因素疾病。血清素及其受体参与抗精神病药物所致的代谢紊乱。本研究调查了4个5-羟色胺受体(5-HT)基因(HTR1A、HTR2A、HTR2C和HTR7)以及血清素转运体(SLC6A4)编码基因中的9个多态性与精神分裂症患者MetS的相关性。

方法

在来自俄罗斯几个西伯利亚地区的475例临床诊断为精神分裂症的患者群体中,研究了一组血清素能系统基因的9个单核苷酸多态性。进行基因分型,并使用卡方检验分析结果。

结果

多态性变体rs521018(HTR2C)与接受长期抗精神病治疗的患者较高的体重指数相关,但与药物所致代谢综合征无关。Rs1150226(HTR2A)也有相关性,但不符合哈迪-温伯格平衡。

结论

我们的结果表明,5-HT基因的等位基因变体可能对代谢参数有影响。MetS的机制背景可能过于复杂,在不将该综合征分解为其各个(因果)组成部分的情况下难以进行研究。

相似文献

1
Genetic Polymorphisms of Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia.精神分裂症患者受体的基因多态性与抗精神病药物所致代谢功能障碍
J Pers Med. 2021 Mar 5;11(3):181. doi: 10.3390/jpm11030181.
2
5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia.精神分裂症中的5-羟色胺受体与迟发性运动障碍
Front Mol Neurosci. 2020 Apr 24;13:63. doi: 10.3389/fnmol.2020.00063. eCollection 2020.
3
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.与接受非典型抗精神病药物治疗的精神分裂症患者代谢综合征相关的 HTR2C 多态性。
Schizophr Res. 2011 Feb;125(2-3):179-86. doi: 10.1016/j.schres.2010.11.030. Epub 2010 Dec 23.
4
Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia.在接受抗精神病药物治疗的精神分裂症患者中,5-羟色胺受体基因多态性对高催乳素血症的调节作用研究。
World J Biol Psychiatry. 2017 Apr;18(3):239-246. doi: 10.1080/15622975.2016.1224926. Epub 2016 Sep 22.
5
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.精神分裂症患者中5-羟色胺2C受体基因多态性、奥氮平引起的体重增加及抗精神病药物引起的代谢综合征:一项荟萃分析
Int J Psychiatry Clin Pract. 2014 Oct;18(4):229-42. doi: 10.3109/13651501.2014.957705. Epub 2014 Sep 18.
6
Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine.HTR2C 和过氧化物酶体增殖物激活受体的遗传多态性与服用氯氮平的精神分裂症患者的代谢综合征无关。
Psychiatry Investig. 2011 Sep;8(3):262-8. doi: 10.4306/pi.2011.8.3.262. Epub 2011 May 26.
7
Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.血清素-2A受体基因(HTR2A)多态性与精神分裂症迟发性运动障碍之间无关联。
Mol Psychiatry. 2001 Mar;6(2):230-4. doi: 10.1038/sj.mp.4000847.
8
Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome.代谢综合征精神分裂症患者中代谢激素调节因子的基因多态性。
Genes (Basel). 2022 May 8;13(5):844. doi: 10.3390/genes13050844.
9
and Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia.与精神分裂症患者接受氟哌啶醇治疗相关的基因多态性和锥体外系副作用。
Int J Mol Sci. 2020 Mar 28;21(7):2345. doi: 10.3390/ijms21072345.
10
Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.德国样本中 HTR2C 基因与抗精神病药引起的体重增加相关,而 LEP 或 INSIG2 基因则没有相关性。
Pharmacogenomics. 2010 Jun;11(6):773-80. doi: 10.2217/pgs.10.50.

引用本文的文献

1
Predictive Role of Serotonin Receptor (5HTR2A) and Dopamine Receptor (DRD2) gene polymorphisms in risperidone-induced weight gain and hyperprolactinemia in patients with schizophrenia.血清素受体(5HTR2A)和多巴胺受体(DRD2)基因多态性在精神分裂症患者利培酮所致体重增加和高泌乳素血症中的预测作用
Eur J Clin Pharmacol. 2025 Jun;81(6):899-905. doi: 10.1007/s00228-025-03835-5. Epub 2025 Apr 2.
2
Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia.基因变异及其在代谢综合征中的作用:一项对精神分裂症患者的研究。
Biomedicines. 2024 Mar 12;12(3):627. doi: 10.3390/biomedicines12030627.
3
Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.布南色林与利培酮治疗精神分裂症的疗效和安全性:系统评价和随机对照试验的荟萃分析。
BMC Psychiatry. 2023 Oct 11;23(1):740. doi: 10.1186/s12888-023-05240-7.
4
Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.布南色林治疗中青年女性精神分裂症的有效性和安全性:来自上市后监测的数据。
BMC Psychiatry. 2023 Feb 21;23(1):115. doi: 10.1186/s12888-023-04598-y.
5
Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome.精神分裂症患者抗精神病药物所致代谢综合征中的代谢激素
J Pers Med. 2022 Oct 5;12(10):1655. doi: 10.3390/jpm12101655.
6
Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance.布南色林在中国精神分裂症患者中的安全性和有效性:一项为期12周的开放标签前瞻性多中心上市后监测的中期分析。
Front Psychiatry. 2022 Aug 18;13:935769. doi: 10.3389/fpsyt.2022.935769. eCollection 2022.
7
The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.DRD2 多态性与精神分裂症患者代谢综合征的性别特异性关联。
Genes (Basel). 2022 Jul 23;13(8):1312. doi: 10.3390/genes13081312.
8
Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome.代谢综合征精神分裂症患者中代谢激素调节因子的基因多态性。
Genes (Basel). 2022 May 8;13(5):844. doi: 10.3390/genes13050844.
9
Psychoneurobiology Research and Personalized Treatment of Schizophrenia.精神神经生物学研究与精神分裂症的个性化治疗
J Pers Med. 2021 Dec 7;11(12):1319. doi: 10.3390/jpm11121319.
10
Search for Possible Associations of Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients.探索精神分裂症患者基因多态性变异与代谢综合征、肥胖及体重指数之间的可能关联。
Pharmgenomics Pers Med. 2021 Sep 7;14:1123-1131. doi: 10.2147/PGPM.S327353. eCollection 2021.

本文引用的文献

1
Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia.精神分裂症患者的脂肪细胞因子与代谢综合征
Metabolites. 2020 Oct 14;10(10):410. doi: 10.3390/metabo10100410.
2
Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome.伴有或不伴有代谢综合征的精神分裂症患者的体脂参数、血糖和血脂谱以及甲状腺激素水平
Diagnostics (Basel). 2020 Sep 10;10(9):683. doi: 10.3390/diagnostics10090683.
3
5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia.精神分裂症中的5-羟色胺受体与迟发性运动障碍
Front Mol Neurosci. 2020 Apr 24;13:63. doi: 10.3389/fnmol.2020.00063. eCollection 2020.
4
Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia.精神分裂症患者中与代谢综合征相关的皮质醇和硫酸脱氢表雄酮
Neuropsychiatr Dis Treat. 2020 Apr 22;16:1051-1058. doi: 10.2147/NDT.S247161. eCollection 2020.
5
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.18种抗精神病药物对精神分裂症患者代谢功能的比较效应、代谢失调的预测因素及其与精神病理学的关联:一项系统评价和网状Meta分析
Lancet Psychiatry. 2020 Jan;7(1):64-77. doi: 10.1016/S2215-0366(19)30416-X. Epub 2019 Dec 17.
6
Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome.伴有或不伴有代谢综合征的精神分裂症患者使用非典型抗精神病药物治疗后体脂及相关生化参数的变化
Front Psychiatry. 2019 Nov 1;10:803. doi: 10.3389/fpsyt.2019.00803. eCollection 2019.
7
Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia.探讨精神分裂症迟发性运动障碍发病机制的药物遗传学作用
Pharmacogenomics. 2019 Nov;20(17):1199-1223. doi: 10.2217/pgs-2019-0100. Epub 2019 Nov 5.
8
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.氯卡色林:临床前和临床药理学及治疗潜力的综述。
Pharmacol Ther. 2020 Jan;205:107417. doi: 10.1016/j.pharmthera.2019.107417. Epub 2019 Oct 16.
9
Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia.精神分裂症患者中与代谢综合征相关的载脂蛋白血清水平
Heliyon. 2019 Jul 3;5(7):e02033. doi: 10.1016/j.heliyon.2019.e02033. eCollection 2019 Jul.
10
The evolutionary old forebrain as site of action to develop new psychotropic drugs.进化古老的前脑是开发新型精神药物的作用部位。
J Psychopharmacol. 2018 Dec;32(12):1277-1285. doi: 10.1177/0269881118798617. Epub 2018 Sep 26.